
Janssen said combination late stage trials for its immunotherapy drug to treat multiple myeloma showed 61% progression-free survival. The company …
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals

